Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 17, Issue 9, Pages 555-558
http://dx.doi.org/10.1155/2003/645751
Brief Communication

Octreotide for Enterocutaneous Fistulas of Crohn’s Disease

A Lavy1 and K Yasin2

1Gastroenterology Unit, Bnai Zion Medical Center, Haifa, Israel
2Gastroenterology Unit, Rambam Medical Center, Haifa, Israel

Received 6 January 2003; Revised 7 July 2003

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Crohn’s disease is a chronic, life-long disease and has many troublesome complications. Fistulas are a part of Crohn’s disease, and although there are many therapeutic modalities used in treating these fistulas they are only partially successful. As we are still very far from being able to cure it, the aim is to improve the patients’ quality of life and to reduce the iatrogenic harm that may be caused by various treatment modalities. Somatostatin is an inhibitor of intestinal secretion and has been used to treat pancreatic and surgical fistulas. Therefore, we decided to treat enterocutaneous fistulas using somatostatin.

METHODS: Five patients with Crohn’s disease were treated with four daily injections of 300 µg octreotide. The total period of treatment was eight weeks.

RESULTS: Closure of fistulas was achieved in four of the five patients.

CONCLUSION: Somatostatin may have a role in treating Crohn’s disease enterocutaneous fistulas and may prevent surgery or prolonged immunosuppressive therapy.